Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CXCR4 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + BMS-936564 Sensitive: C2 – Inclusion Criteria ibrutinib + BMS-936564 Sensitive : C2	ibrutinib + BMS-936564 Sensitive: C2 – Inclusion Criteria ibrutinib + BMS-936564 Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3